Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ursane-type triterpenoids, such as ursolic acid, have been investigated for their potential neuroprotective and anti-inflammatory properties, which are relevant to the pathology of Multiple Sclerosis (MS). Several preclinical studies have demonstrated that ursolic acid can reduce neuroinflammation, inhibit microglial activation, and protect against demyelination in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE). For example, a 2016 study in Scientific Reports showed that ursolic acid ameliorated EAE in mice by modulating immune responses and reducing infiltration of inflammatory cells into the central nervous system.

Despite these promising preclinical results, there is a lack of robust clinical evidence in humans. No large-scale, randomized controlled trials have confirmed the efficacy or safety of ursane-type triterpenoids in MS patients. Most data originate from in vitro experiments or animal studies. Consequently, while there is some scientific rationale and preliminary evidence supporting their potential use, the current level of evidence remains low. Further research, particularly in human populations, is necessary to determine the therapeutic potential and safety of ursane-type triterpenoids in the treatment or support of MS.

More about Ursane-type triterpenoid
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Ursane-type triterpenoid

Products containing Ursane-type triterpenoid